Routine auditor change with no red flags, no trading implications. Monitor next 20-F for any unexpected audit-related disclosures, but this filing alone does not warrant action.
RDY drugs
RDY drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 23 $11.80entry
- T+1 · 4mo ago −0.08%α −0.19% · $11.79
- T+5 · 4mo ago +0.25%α −0.22% · $11.83
- T+20 · 3mo ago +2.63%α −0.68% · $12.11
- T+60 · 5w ago +9.32%α +4.77% · $12.90
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's Laboratories filed a Form 6-K reporting a routine auditor change from Ernst & Young Associates LLP to Deloitte Haskins & Sells LLP, driven by mandatory rotation under Indian law. The filing confirms no disagreements, adverse opinions, or reportable events with the prior auditor, and EY has agreed with the company's statements. This is a standard governance update with no material financial or operational implications.
Key Facts
- Auditor change from Ernst & Young Associates LLP to Deloitte Haskins & Sells LLP, effective for FY2027 audit
- Mandatory rotation under Section 139 of the Indian Companies Act, 2013
- No disagreements or reportable events with prior auditor during FY2026 or FY2025
- Prior auditor's audit reports contained no adverse opinion, disclaimer, or qualification
- Deloitte appointment approved by Board on July 22, 2026, subject to shareholder approval
Financial Impact
No financial impact, routine auditor change with no disagreements or restatements
Risk Factors
- None material, auditor change is mandatory and uncontested
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000528 |
| Document: 0001575872-26-000528-index.html | 0001575872-26-000528 |
| Document: 0001575872-26-000528.txt | 0001575872-26-000528 |
Track record
73 reports on RDY
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers